Boothbay Fund Management LLC Buys Shares of 26,437 Bristol-Myers Squibb (NYSE:BMY)

Boothbay Fund Management LLC acquired a new position in Bristol-Myers Squibb (NYSE:BMY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 26,437 shares of the biopharmaceutical company's stock, valued at approximately $1,495,000.

Several other large investors have also modified their holdings of BMY. Morse Asset Management Inc increased its position in Bristol-Myers Squibb by 25.0% in the 3rd quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock worth $517,000 after buying an additional 2,000 shares during the period. Tudor Financial Inc. acquired a new stake in shares of Bristol-Myers Squibb in the third quarter worth $250,000. Pine Valley Investments Ltd Liability Co raised its stake in Bristol-Myers Squibb by 1.3% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company's stock valued at $2,323,000 after purchasing an additional 575 shares during the last quarter. World Investment Advisors LLC boosted its holdings in Bristol-Myers Squibb by 18.7% in the 3rd quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock valued at $2,282,000 after purchasing an additional 6,954 shares during the period. Finally, Arvest Bank Trust Division acquired a new stake in Bristol-Myers Squibb in the 3rd quarter worth $1,724,000. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Trading Down 1.3 %

NYSE:BMY traded down $0.67 during trading hours on Thursday, hitting $49.53. 17,161,789 shares of the stock were exchanged, compared to its average volume of 12,973,691. The company has a market capitalization of $100.79 billion, a P/E ratio of -11.21, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The company's 50 day moving average is $55.99 and its two-hundred day moving average is $56.41. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter last year, the business earned ($4.40) earnings per share. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 5.01%. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Analysts Set New Price Targets

Several research firms recently weighed in on BMY. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Truist Financial raised their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. UBS Group lowered their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company boosted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Finally, Citigroup raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb has a consensus rating of "Hold" and a consensus target price of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.